Style | Citing Format |
---|---|
MLA | Iraji A, et al.. "Synthesis, Biological Evaluation and Molecular Modeling Studies of Methyl Indole-Isoxazole Carbohydrazide Derivatives As Multi-Target Anti-Alzheimer’S Agents." Scientific Reports, vol. 14, no. 1, 2024, pp. -. |
APA | Iraji A, Nikfar P, Nazari Montazer M, Karimi M, Edraki N, Saeedi M, Mirfazli SS (2024). Synthesis, Biological Evaluation and Molecular Modeling Studies of Methyl Indole-Isoxazole Carbohydrazide Derivatives As Multi-Target Anti-Alzheimer’S Agents. Scientific Reports, 14(1), -. |
Chicago | Iraji A, Nikfar P, Nazari Montazer M, Karimi M, Edraki N, Saeedi M, Mirfazli SS. "Synthesis, Biological Evaluation and Molecular Modeling Studies of Methyl Indole-Isoxazole Carbohydrazide Derivatives As Multi-Target Anti-Alzheimer’S Agents." Scientific Reports 14, no. 1 (2024): -. |
Harvard | Iraji A et al. (2024) 'Synthesis, Biological Evaluation and Molecular Modeling Studies of Methyl Indole-Isoxazole Carbohydrazide Derivatives As Multi-Target Anti-Alzheimer’S Agents', Scientific Reports, 14(1), pp. -. |
Vancouver | Iraji A, Nikfar P, Nazari Montazer M, Karimi M, Edraki N, Saeedi M, et al.. Synthesis, Biological Evaluation and Molecular Modeling Studies of Methyl Indole-Isoxazole Carbohydrazide Derivatives As Multi-Target Anti-Alzheimer’S Agents. Scientific Reports. 2024;14(1):-. |
BibTex | @article{ author = {Iraji A and Nikfar P and Nazari Montazer M and Karimi M and Edraki N and Saeedi M and Mirfazli SS}, title = {Synthesis, Biological Evaluation and Molecular Modeling Studies of Methyl Indole-Isoxazole Carbohydrazide Derivatives As Multi-Target Anti-Alzheimer’S Agents}, journal = {Scientific Reports}, volume = {14}, number = {1}, pages = {-}, year = {2024} } |
RIS | TY - JOUR AU - Iraji A AU - Nikfar P AU - Nazari Montazer M AU - Karimi M AU - Edraki N AU - Saeedi M AU - Mirfazli SS TI - Synthesis, Biological Evaluation and Molecular Modeling Studies of Methyl Indole-Isoxazole Carbohydrazide Derivatives As Multi-Target Anti-Alzheimer’S Agents JO - Scientific Reports VL - 14 IS - 1 SP - EP - PY - 2024 ER - |